Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + bevacizumab with carboplatin-paclitaxel or pemetrexed in EGFR-mutant NSCLC after EGFR TKI resistance
KCT0005588Phase 2Completed
- Sponsor
- Yonsei University Health System
- Start
- Oct 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Atezolizumab + bevacizumab + carboplatin + paclitaxel with Atezolizumab + bevacizumab + pemetrexed (2 arms). Primary endpoint: Progression-free survival rate at 12 months. Started Oct 2021; status: completed.
02
Drugs
atezolizumabbevacizumabcarboplatinpaclitaxelpemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on KCT0005588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005588.